1) Innovent has positioned itself at the forefront of China’s GLP-1 market with Mazdutide, the first-in-class dual GCG/GLP-1 receptor agonist approved for obesity and overweight in June 2025.
The Healthy @Reader's Digest on MSN
What’s your “cardiac age”? A Cleveland Clinic heart doctor explains how to calculate it
Here's how to tell if your heart is trending towards accelerated aging—and what to do if it is, according to an expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback